TrkB gene transfer protects retinal ganglion cells from axotomy-induced death in vivo

Li Cheng1, Przemyslaw Sapieha, Pavla Kittlerova

  • 1Department of Pathology and Cell Biology, Université de Montréal, Montreal, Quebec H3T 1J4, Canada.

Insights

Enhancing neurotrophin receptor capacity improves survival of injured neurons. Gene transfer and growth factor treatment protected retinal ganglion cells (RGCs) after optic nerve injury, offering a potential neuroprotective strategy.

Area of Science:

  • Neuroscience
  • Cell Biology
  • Regenerative Medicine

Background:

  • Injury can decrease neurotrophin receptor expression, hindering neuronal survival.
  • Retinal ganglion cells (RGCs) are vulnerable to death following central nervous system (CNS) injury, such as optic nerve transection.

Purpose of the Study:

  • To test if reduced neurotrophin receptor expression limits neuronal survival after CNS injury.
  • To investigate if enhancing neurotrophin receptor signaling can promote survival of injured RGCs.

Main Methods:

  • Utilized an adult rat optic nerve transection model to study RGC death.
  • Measured TrkB mRNA levels in axotomized RGCs.
  • Employed TrkB gene transfer and Brain-Derived Neurotrophic Factor (BDNF) administration.
  • Assessed neuronal survival rates and downstream signaling pathways (MAPK, PI3K).

Main Results:

  • TrkB mRNA levels significantly decreased in RGCs post-axotomy.
  • Combined TrkB gene transfer and BDNF treatment resulted in 76% RGC survival at 2 weeks, compared to >90% loss without treatment.
  • TrkB-mediated survival required mitogen-activated protein kinase (MAPK) activation, but not phosphatidylinositol-3 kinase (PI3K) activation.

Conclusions:

  • Downregulation of neurotrophin receptors after injury impairs neuronal survival.
  • Enhancing injured neurons' capacity to respond to trophic factors, like BDNF via TrkB, is a viable neuroprotective strategy for the adult CNS.
  • This approach shows promise for treating neurodegenerative conditions and CNS injuries.